Three drug discovery projects have been named recipients of the 2021 OCTRI’s Biomedical Innovation Program in the program’s drug discovery track. This BIP track supports drug discovery platforms and early-stage therapeutic technology projects, including validation of drug targets and development of small molecules, antibodies, vaccines or biologics.
BIP awards provide funding, project management and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace.
2021 BIP award winners
Pictured above: BIP awardees Mallesh Pandrala, Ph.D., Nabil J. Alkayed, M.D., Ph.D., Sanjay V. Malhotra, Ph.D.
See the project abstracts.
Nabil J. Alkayed, M.D., Ph.D., professor of anesthesiology and perioperative medicine, James Metcalfe Chair in Cardiovascular Research, director of research at the Knight Cardiovascular Institute
A novel therapeutic target in subarachnoid hemorrhage (SAH)
Mallesh Pandrala, Ph.D., assistant staff scientist at the OHSU Knight Cancer Institute’s Center for Experimental Therapeutics
Development of a pan-BCR-ABL inhibitor for chronic myeloid leukemia with improved safety
Sanjay V. Malhotra, Ph.D., professor of cell development and cancer biology, co-director of the Center for Experimental Therapeutics at the Knight Cancer Institute
Co-investigators: Marie Foss and Alexander Honkala, researchers with the Center for Experimental Therapeutics
Addressing paclitaxel resistance and disease progression in ovarian cancer with small molecule YBX1 inhibitors
The BIP Awards program, now in its ninth year, is a collaboration of the OHSU Oregon Clinical and Translational Research Institute, OHSU Technology Transfer and OHSU Collaborations and Entrepreneurship. Award funding is provided by OCTRI and the OHSU Foundation via the University Venture Development Fund.
